Syngene International growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+2.6%+4.4%+9.3%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−11.8%+2.7%+8.6%
−23.6%+3.5%+3.6%
−36.2%−2.7%+9.8%
−36.3%−2.8%+9.7%
+3.8%+10.5%+5.5%
+2.4%+11.0%+17.7%
−21.6%+12.0%+26.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SYNGENE₹398.60

Syngene International Ltd.

· Pharma & Health
₹ CrorePeersSAILIFEDIVISLABWOCKPHARMAGLANDASTERDMPPLPHARMACOHANCELALPATHLABMcap ₹16,060 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+9.3+4.4+2.6—
EBITDA Growth—+8.6+2.7-11.8—
EBIT Growth—+3.6+3.5-23.6—
Net Income Growth—+9.8-2.7-36.2—
EPS Growth—+9.7-2.8-36.3—
Total Assets Growth—+5.5+10.5+3.8—
Total Equity Growth—+17.7+11.0+2.4—
Cash from Operations Growth—+26.5+12.0-21.6—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.